CD9 and glioblastoma: Our data demonstrated a significant increase in LDHA+/CD9+EVs (p < 0.001) and S100A8/9+/CD9+EVs (p < 0.05) in the plasma of recurrent GBM patients, compare to the NR and HD group (Figure 3D).